Coya Therapeutics, Inc. (NASDAQ:COYA – Get Free Report) was the recipient of a large increase in short interest in May. As of May 31st, there was short interest totalling 207,000 shares, an increase of 20.0% from the May 15th total of 172,500 shares. Currently, 1.6% of the company’s shares are sold short. Based on an average trading volume of 77,000 shares, the short-interest ratio is currently 2.7 days.
Analysts Set New Price Targets
Several research analysts have recently weighed in on COYA shares. Rodman & Renshaw started coverage on Coya Therapeutics in a research report on Thursday. They issued a “buy” rating and a $18.00 price objective for the company. Chardan Capital reaffirmed a “buy” rating and issued a $14.00 target price on shares of Coya Therapeutics in a research report on Wednesday, June 5th.
Read Our Latest Research Report on Coya Therapeutics
Hedge Funds Weigh In On Coya Therapeutics
Coya Therapeutics Trading Down 7.5 %
Coya Therapeutics stock traded down $0.58 during midday trading on Friday, reaching $7.20. The stock had a trading volume of 101,247 shares, compared to its average volume of 55,578. Coya Therapeutics has a 12 month low of $3.21 and a 12 month high of $10.69. The company has a market capitalization of $105.26 million, a P/E ratio of -8.47 and a beta of 0.77. The company has a fifty day moving average price of $8.19 and a two-hundred day moving average price of $7.88.
Coya Therapeutics (NASDAQ:COYA – Get Free Report) last issued its earnings results on Thursday, May 9th. The company reported ($0.35) EPS for the quarter. The company had revenue of $0.13 million during the quarter. On average, equities research analysts predict that Coya Therapeutics will post -1.3 earnings per share for the current fiscal year.
Coya Therapeutics Company Profile
Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Further Reading
- Five stocks we like better than Coya Therapeutics
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- MarketBeat Week in Review – 6/10 – 6/14
- Consumer Discretionary Stocks Explained
- Top 5 High-Performance Cryptocurrency ETFs to Watch
- With Risk Tolerance, One Size Does Not Fit All
- 3 Stocks That Plummeted After the Post-Fed Speech Crash
Receive News & Ratings for Coya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.